NCT05785715 2025-07-01
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie
Phase 2 Terminated
AbbVie
Janssen Research & Development, LLC
Prometheus Laboratories
University Health Network, Toronto